FIA
JNCE

FNY Investment Advisers’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

FNY Investment Advisers’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,000
Closed -$27K – 768
2023
Q1 		$27K Buy
+15,000
New +$18.6K 0.03% 239

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

FNY Investment Advisers's JNCE Position: Q2 2023 in Review

FNY Investment Advisers sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 15,000 shares — an estimated $27K sold.

FNY Investment Advisers first reported a position in JNCE in Q1 2023 and held it in 1 quarter. The position peaked at $27K in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • FNY Investment Advisers reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 15,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $27K.
  • FNY Investment Advisers first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • FNY Investment Advisers's Jounce Therapeutics, Inc. Common Stock position peaked at $27K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on FNY Investment Advisers's 13F filing for Q2 2023, filed 11 Jul 2023.